Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy

(2021) Cecilia Fazio et al.   Human Vaccines & Immunotherapeutics

Synergic complement‐mediated bactericidal activity of monoclonal antibodies with distinct specificity

(2020) Eriberto Noel Natali et al.   FASEB JOURNAL

First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England

(2020) Shamez N Ladhani et al.   CLINICAL INFECTIOUS DISEASES

Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines

(2018) Leszek Szenborn et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes

(2018) M. Giuliani et al.   Scientific Reports

Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults

(2018) Xavier Sáez-Llorens et al.   Human Vaccines & Immunotherapeutics

Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines

(2018) Rodolfo Villena et al.   Human Vaccines & Immunotherapeutics

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents – Results from a randomized, controlled, observer-blind phase II study

(2018) Jo Anne Welsch et al.   VACCINE

Meningococcal serogroups and surveillance: a systematic review and survey

(2018) Meagan E Peterson et al.   Journal of Global Health

An unwanted guest: Neisseria meningitidis – carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence

(2017) Elena Gianchecchi et al.   Expert Review of Anti-Infective Therapy

Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study

(2017) Helen Petousis-Harris et al.   LANCET

The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines

(2016) Stephen I. Pelton   JOURNAL OF ADOLESCENT HEALTH

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

(2016) Sydel R Parikh et al.   LANCET

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants

(2016) Stan L. Block et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Enter B and W: two new meningococcal vaccine programmes launched

(2015) Shamez N Ladhani et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents

(2015) Xavier Saez-Llorens et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines after Co-administration

(2015) Roberto Gasparini et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

(2015) Jamie Findlow et al.   VACCINE

Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study

(2015) Kirsten P. Perrett et al.   VACCINE

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial

(2015) Stan L. Block et al.   VACCINE

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents

(2015) Xavier Saez-Llorens et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers

(2014) Miguel Tregnaghi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II)

(2014) Susanna Esposito et al.   Human Vaccines & Immunotherapeutics

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)

(2014) Roman Prymula et al.   Human Vaccines & Immunotherapeutics

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age

(2013) Terry M Nolan et al.   Human Vaccines & Immunotherapeutics

Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae

(2012) Ronza Hadad et al.   APMIS

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

(2012) Eva Hong et al.   VACCINE

Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidis

(2011) Puiying A. Mak et al.   Clinical and Vaccine Immunology

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Menveo®: a novel quadrivalent meningococcal CRM197conjugate vaccine against serogroups A, C, W-135 and Y

(2010) Brian Cooper et al.   Expert Review of Vaccines

Meningococcal carriage by age: a systematic review and meta-analysis

(2010) Hannah Christensen et al.   LANCET INFECTIOUS DISEASES

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers

(2009) S. A. Halperin et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES